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Abstract
Background: The ability of T-cells to traffic to and penetrate tumors impacts the clinical efficacy of T-cell therapy
therefore methods to track transferred T-cells in vivo are needed. In this preliminary report, we evaluated the use of
concurrent SPECT/PET-CT imaging to monitor the egress of HER-2/neu specific T-cells in a breast cancer patient
with extensive bone-only metastatic disease.
Findings: Indium (In-111) labeled T-cells demonstrated similar or greater viability than unlabeled T-cells at either a
low or high dose of In-111 over a 24-h incubation period in vitro. The function of labeled or unlabeled T-cells was
not significantly different (p > 0.05) at either dose. T-cells trafficked to all sites of metastatic disease and infiltrated
the tumor as assessed by SPECT imaging. In-111 uptake at 24 h after infusion varied from 3.8 (right proximal
humerus) to 6.3 (right sacrum) background corrected counts per pixel and remained elevated at 48 h. Concurrent
PET-CT imaging demonstrated a fluorodeoxyglucose flare, measured by increase in tumor site uptake as high as
32 % and at most sites of disease at 48 h. This flare was associated with focal pain after T-cell infusion at metastatic
sites. The patient had stable disease for 18 months after completion of T-cell therapy.
Conclusion: Concurrent SPECT/PET-CT imaging, over a 48-h period after T-cell infusion, provided evidence of T-cell
homing to all disease sites as well as a tumor metabolism flare response. This technique may be useful for
monitoring T-cell trafficking after autologous as well as chimeric antigen receptor T-cell infusion.
Trial Registraion: Trial registered at ClinicalTrials.gov registration number NCT00791037, registered 13 November
2008.
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Background
Adoptive T-cell therapy using chimeric antigen receptor,
tumor infiltrating, or antigen specific T-cells shows sig-
nificant clinical responses in hematologic cancers but
few durable responses in solid tumors [1–3].Limitations
include the inability of antigen specific T-cells to traffic
to and penetrate solid tumors and significant variations
in tumor T-cell infiltration [4]. For example, in adoptive
transfer of HER2 specific T-cells, indium 111 (In-111)
labeled cells could traffic to the bone marrow but not to
liver metastases [5]. Methods are needed to monitor in-
fused T-cells in vivo, evaluate their function, and demon-
strate whether T-cells penetrate all metastatic sites.
Readily accessible approaches for monitoring T cells in
vivo are tracking T-cells labeled with In-111 by single pho-
ton emission computed tomography (SPECT) imaging or
evaluating T-cell activity by fluorodeoxyglucose positron
emission tomography (PET-CT) [6]. As part of a clinical
trial, we piloted the concurrent use of SPECT and PET-CT
imaging to assess the homing capability and inflammatory
function of adoptively transferred antigen specific T-cells at
various metastatic sites.
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Findings
Indium-111 labeling does not impact T-cell viability nor
diminish antigen specific cytokine secretory function
T-cells labeled with 49uCi and 480uCi demonstrated simi-
lar viability as compared with unlabeled cells at 24 h when
plated at comparable cell concentrations (Fig. 1a). After IL-
2 stimulation, 49uCi labeled T-cells were 93.7 ± 1.1 % viable
(p = 0.16) and 480uCi labeled T-cells were 90.9 ± 0.3 %
viable (p = 0.03) as compared to unlabeled T-cells. After
CD3/CD8 stimulation, 49uCi labeled T-cells were 93.9 ±
2.7 % viable (p = 0.537) and 480uCi labeled T-cells were
85.7 ± 0.0 % viable (p = 0.08) as compared to unlabeled T-
cells. At 4 h there were no statistically significant differ-
ences between groups (Fig. 1a).
In-111 labeling did not diminish the ability of T-
cells to secrete IFN-gamma (IFN-g). When cultured
with IL-2, 49uCi labeled T-cells secreted 336.0 ± 25.4 pg/
mL (p = 0.09) and 480uCi labeled T-cells 194.5 ± 16.3 pg/
mL (p = 0.07) IFN-g as compared to unlabeled T-cells.
49uCi labeled T-cells 1215.0 ± 8.5 pg/mL (p = 0.03) and
480uCi labeled T-cells 1139.0 ± 46.7 pg/mL (p = 0.02) se-
creted more IFN-g in response to CMV antigen than
unlabeled cells. All groups responded equally to stimula-
tion with CD3/CD28 beads (p < 0.05 for all groups)
(Fig. 1b).
HER2 specific T-cells trafficked to and infiltrated all sites
of metastatic disease by 48 h
The patient had known metastases to her skull, sternum,
bilateral proximal humeri, and right sacrum. Labeled
HER2 specific T-cells trafficked to all metastatic sites of
disease by 24 h (Fig. 2a). Figure 2b shows a representative
example of labeled T-cell infiltration into both humeral
metastases. At 24 h the corrected In-111 uptake varied
from the left proximal humerus at 2.3 corrected counts
per pixel (ccpp) to the right sacrum at 6.3 ccpp. By 48 h,
the corrected In-111 uptake had increased by 44 % in the
right proximal humerus, 56 % in the left proximal hu-
merus, 28 % in the sternum, and 9 % in the right sacrum.
Similar to other studies, In-111 uptake was present in the
spleen, liver, and heart at 4 h and remained in these organs
at 48 h (Fig. 2c) [7, 8].
FDG PET-CT demonstrated acute increases in tumor
metabolism at most metastatic sites 48 h after T-cell
infusion
FDG PET-CT imaging demonstrated increased FDG up-
take at most sites of metastatic disease by 48 h suggesting
the trafficking HER2 specific T-cells were functional and
activated (Fig. 3a). There was between 17 % (left axillary
lymph node) and 32 % (sternum) increase compared to
baseline scans (Fig. 3c). These increases in standardized
uptake value (SUV) in metastases are higher than the 6 %
increased physiologic uptake in the liver (Fig. 3c). Further-
more, SUV uptake in the left axillary lymph node was
higher than soft tissue background both at baseline (ratio of
lymph node metastasis to soft tissue background is 2.0) and
at 48 h (ratio of 2.69) and the SUV uptake in the humeral
bone metastases were higher than background bone mar-
row uptake both at baseline (ratio of left humoral metasta-
sis to left bone marrow background is 1.44) and at 48 h
(ratio of left humoral metastasis to left bone marrow back-
ground is 1.8). The right sacrum did not have an increase
in uptake at 48 h, with FDG SUV lower than liver control.
The increased FDG uptake at sites of metastatic disease
was not evident 3 months after infusion (Fig. 3b).
a
b
Fig. 1 Indium-111 labeling does not impact T-cell viability nor diminish
antigen specific cytokine secretory function. a Cell viability of unlabeled
controls (white), 48uCi (grey), and 490uCi labeled T-cells (black) in media
only, with IL-2, or CD3/CD28 bead stimulation after culture for 4 and
24 h. b Levels of IFN-g (pg/ml) secreted in 48 h culture supernatants of
unlabeled controls (white), 48uCi (grey), and 490uCi (black) labeled T-cells
cultured with media only, IL-2, after CMV antigen stimulation, or CD3/
CD28 stimulation. Columns and bars represent the mean of duplicates
(± SE) for each condition for both donors
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Location of FDG tumor uptake mirrored the patient’s
report of grade 1 or 2 bone pain flares localized to sites of
metastatic disease experienced with successive T-cell infu-
sions. After completion of T-cell infusions, the patient had
similar boney pain during HER2 specific booster vaccina-
tions. On completion of the study, the patient experienced
stable disease without changes in therapy for 18 months.
Conclusion
The use of SPECT imaging is an effective modality for
tracking T-cells in vivo without impacting their function.
Early trials have demonstrated that Melan-A-specific
cytotoxic T-cells labeled with In-111 can traffic to sites
of metastasis by 48 h and remain up to 14 days [8]. We
demonstrate T-cells homing to multiple sites of breast
cancer deposits through In-111 labeling.
Changes in FDG tumor uptake quantitated by PET-CT
are a functional measure usually associated with disease
progression. In 28 breast cancer patients with bone domin-
ant disease, higher tumor SUV predicted a shorter time to
disease progression (p < 0.006) [9]. In our patient, an acute
increase in tumor FDG uptake was associated with disease
stabilization. After adoptive T-cell therapy for nasopharyn-
geal carcinoma or breast cancer, pain at sites of disease
temporally related to T-cell infusion correlated with clinical
response in specific lesions [3, 10]. Acute increases in
tumor metabolism by FDG PET-CT allows quantitation of
inflammation induced by activated T-cells and may provide
a measure of the level needed for disease regression. More
data is needed to calculate a correlation of clinical response
with specific changes in SUV.
Optimizing adoptive T-cell therapy for all patients re-
quires an understanding of the trafficking and function of
these cells in vivo. This pilot data demonstrates that con-
current In-111 T-cell SPECT and FDG PET-CT imaging,
modalities available at any US medical center, can evaluate
T-cell homing, tumor penetration by T-cells, and T-cell
induced inflammation. These preliminary findings will be
expanded in further trials.
Materials and methods
T-cell viability and cytokine secretion after In-111 labeling
Peripheral blood mononuclear cells (PBMC) were ob-




Fig. 2 HER2 specific T-cells trafficked to and infiltrated all sites of
metastatic disease over a 48 h period. a Whole body planar images
of In-111 labeled T-cells (i) anterior and (ii) posterior views 24 h after
infusion show focal areas of increased uptake in the left postero-lateral
skull, both humeral heads, mid-sternum, and R sacrum (arrows).
b SPECT/CT fused image of In-111 T-cells acquired 24 h post infusion;
humeral heads show T-cell infiltrates (pink). c In-111 uptake in counts/
pixel normalized to background at 4 h (white), 24 h (grey), and 48 h
(black) after infusion
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were cultured with CD3/CD28 beads (Life Technolo-
gies), diluted 0.6-1x106/ml, and cultured with IL-2 (30U/
ml) every 3 days. Day 12, CD3/CD28 beads were re-
moved and expanded T-cells, >90 % CD3+, were labelled
with 48uCi or 490uCi In-111 at GE Healthcare (Seattle,
WA). 2 mCi In-111 oxine (Covidien) was added to
200x106 cultured T-cells for 30 min and resuspended in
media with non-labelled cells as controls. Cells (1x106/
ml per group) were cultured at 37 °C with (1) media
only, (2) IL-2 (30U/ml), (3) CD3/CD28 beads (2:1 ratio),
or (4) CMV lysate (2.5ug/ml) with irradiated autologous
PBMC. 100ul cell suspension was removed at 4 and
24 h. Numbers of live and dead cells were counted in
duplicate using trypan blue exclusion and percent viabil-
ity calculated. Supernatants were collected from the
cultured cells 48 h after stimulation and IFN-g release
was measured using ELISA (eBioscience).
Clinical protocol
After informed consent, the patient was enrolled in IRB
approved trial NCT00791037. Imaging protocols were
approved by IRB and radiation safety. Enrollment criteria
included (1) metastatic treatment refractory HER2+ cancer,
(2) lesions quantifiable by imaging, and (3) no cytotoxic
chemotherapy for 1 month before the first T-cell infusion.
The patient was vaccinated with three HER2 specific
peptide-based vaccines weekly for 3 weeks [11]. Two weeks
after the last vaccine, PBMC were collected by leukapher-
esis and expanded ex vivo as previously described [3]. Cells
were administered as a dose escalation with 5x109 (dose 1),
5x1010 (dose 2), and 5x1011 (dose 3) total cells.
Indium labeling and SPECT imaging
1 mCi In-111 oxine (Covidien) was added to 10x106 HER2
antigen cultured T-cells for 30 min at room temperature
and resuspended in normal saline (GE Healthcare Nuclear
Pharmacy). Labeled cells were infused prior to the third T-
cell infusion. Migration of T-cells was evaluated at 4, 24
and 48 h by whole body planar and SPECT scintigraphy
gamma camera imaging (Phillips Precedence; GE Medical
Systems) equipped with medium energy collimators. In-111
lesion uptake was quantified by region of interest (ROI) in
each metastasis with background subtracted from adjacent
soft tissues in counts/pixel. At each time point an aliquot of




Fig. 3 FDG PET-CT demonstrates acute increases in SUV at most metastatic sites over a 48 h period after T-cell infusion. a FDG PET-CT image 48 h post
T-cell infusion. b FDG PET-CT image 3 months following T-cell infusion. c FDG uptake as % increase over baseline 48 h
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for image analysis. Data is reported as counts/pixel normal-
ized to background (ccpp).
PET-CT imaging
The patient was injected with an activity of 310 MBq
(10 mCi) of fluorodeoxyglucose (FDG). Imaging was
performed by PET-CT scanner (Discovery LS; GE Medical
Systems) in high sensitivity mode and consisted of a torso
survey covering 5 adjacent 15-cm axial fields. Baseline FDG
PET-CT scan was performed in parallel with SPECT im-
aging prior to infusion and at 48 h. FDG PET-CT was also
performed 3 months after the last T-cell infusion. The FDG
uptake in metastases was measured as the tumor ROI
compared to an equivalent background normalized by
injected dose (SUV). Change in FDG uptake early after
T-cell infusion was reported as the ratio of FDG SUV
per metastatic site increase compared to baseline.
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